JP2016537012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537012A5 JP2016537012A5 JP2016542333A JP2016542333A JP2016537012A5 JP 2016537012 A5 JP2016537012 A5 JP 2016537012A5 JP 2016542333 A JP2016542333 A JP 2016542333A JP 2016542333 A JP2016542333 A JP 2016542333A JP 2016537012 A5 JP2016537012 A5 JP 2016537012A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- nucleic acid
- seq
- encoded
- calreticulin gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 404
- 108020004707 nucleic acids Proteins 0.000 claims description 379
- 102000039446 nucleic acids Human genes 0.000 claims description 379
- 108090000623 proteins and genes Proteins 0.000 claims description 296
- 102000004169 proteins and genes Human genes 0.000 claims description 277
- 239000002773 nucleotide Substances 0.000 claims description 165
- 125000003729 nucleotide group Chemical group 0.000 claims description 165
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 118
- 108090000549 Calreticulin Proteins 0.000 claims description 96
- 238000000034 method Methods 0.000 claims description 91
- 108700028369 Alleles Proteins 0.000 claims description 68
- 230000000295 complement effect Effects 0.000 claims description 49
- 230000002068 genetic effect Effects 0.000 claims description 47
- 229920001184 polypeptide Polymers 0.000 claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 33
- 239000003112 inhibitor Substances 0.000 claims description 30
- 231100000221 frame shift mutation induction Toxicity 0.000 claims description 29
- 230000037433 frameshift Effects 0.000 claims description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 27
- 102000004082 Calreticulin Human genes 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 7
- 238000003364 immunohistochemistry Methods 0.000 claims description 6
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 206010028537 myelofibrosis Diseases 0.000 claims description 4
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 4
- 238000012163 sequencing technique Methods 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 238000003753 real-time PCR Methods 0.000 claims description 3
- 238000012340 reverse transcriptase PCR Methods 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 208000009527 Refractory anemia Diseases 0.000 claims description 2
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims description 2
- 208000005485 Thrombocytosis Diseases 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 238000002493 microarray Methods 0.000 claims description 2
- 230000009149 molecular binding Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 108020004491 Antisense DNA Proteins 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 239000003816 antisense DNA Substances 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108091060271 Small temporal RNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13184632.1 | 2013-09-16 | ||
| EP13184632 | 2013-09-16 | ||
| EP13186939.8 | 2013-10-01 | ||
| EP13186939 | 2013-10-01 | ||
| US201361909313P | 2013-11-26 | 2013-11-26 | |
| US61/909,313 | 2013-11-26 | ||
| PCT/EP2014/069638 WO2015036599A1 (en) | 2013-09-16 | 2014-09-15 | Mutant calreticulin for the diagnosis of myeloid malignancies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020022378A Division JP2020109092A (ja) | 2013-09-16 | 2020-02-13 | 骨髄性悪性腫瘍の診断のための突然変異体カルレチクリン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537012A JP2016537012A (ja) | 2016-12-01 |
| JP2016537012A5 true JP2016537012A5 (enExample) | 2017-11-02 |
| JP6745220B2 JP6745220B2 (ja) | 2020-08-26 |
Family
ID=51795161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542333A Active JP6745220B2 (ja) | 2013-09-16 | 2014-09-15 | 骨髄性悪性腫瘍の診断のための突然変異体カルレチクリン |
| JP2022177306A Active JP7646221B2 (ja) | 2013-09-16 | 2022-11-04 | 骨髄性悪性腫瘍の診断のための突然変異体カルレチクリン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022177306A Active JP7646221B2 (ja) | 2013-09-16 | 2022-11-04 | 骨髄性悪性腫瘍の診断のための突然変異体カルレチクリン |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9371570B2 (enExample) |
| EP (5) | EP2808338B1 (enExample) |
| JP (2) | JP6745220B2 (enExample) |
| KR (1) | KR102433548B1 (enExample) |
| CN (3) | CN105916876A (enExample) |
| AU (2) | AU2014320262B2 (enExample) |
| BR (1) | BR112016005611B1 (enExample) |
| CA (1) | CA2924370C (enExample) |
| DK (3) | DK3494985T3 (enExample) |
| ES (2) | ES2577289T3 (enExample) |
| MX (1) | MX348980B (enExample) |
| PL (2) | PL2808338T3 (enExample) |
| PT (1) | PT2808338E (enExample) |
| RU (1) | RU2668808C2 (enExample) |
| SG (1) | SG11201601193TA (enExample) |
| WO (1) | WO2015036599A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2808338B1 (en) | 2013-09-16 | 2016-03-30 | CeMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH | Mutant calreticulin for the diagnosis of myeloid malignancies |
| WO2016077409A1 (en) * | 2014-11-12 | 2016-05-19 | Neogenomics Laboratories, Inc. | Determining tumor load and biallelic mutation in patients with calr mutation using peripheral blood plasma |
| WO2016087514A1 (en) * | 2014-12-02 | 2016-06-09 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
| EP3277293A4 (en) * | 2015-03-30 | 2019-01-16 | Jeffrey Thomas Loh | PROCESS FOR IN VITRO PRODUCTION OF BLOOD PLATES AND COMPOSITIONS AND USES THEREOF |
| US10519509B2 (en) | 2015-04-23 | 2019-12-31 | Quest Diagnostics Investments Incorporated | Methods and compositions for the detection of CALR mutations in myeloproliferative diseases |
| KR101953092B1 (ko) * | 2015-11-11 | 2019-06-13 | 가톨릭대학교 산학협력단 | Ｂｃｒ／ａｂｌ 음성 골수증식종양 관련 유전자변이 다중검출용 펩티드핵산 프로브, 이를 포함하는 유전자변이 다중검출 조성물, 다중검출 키트 및 유전자변이 다중검출방법 |
| ITUA20162858A1 (it) * | 2016-04-26 | 2017-10-26 | Univ Degli Studi Di Torino | Procedimento per la rivelazione di mutazioni di tipo 1 e 2 del gene calreticulina (calr) e relativo kit |
| CN109803674A (zh) * | 2016-06-10 | 2019-05-24 | Io生物技术公司 | Calr和jak2疫苗组合物 |
| CN106566875A (zh) * | 2016-09-20 | 2017-04-19 | 上海荻硕贝肯医学检验所有限公司 | 用于检测骨髓异常增生综合征mds基因突变的引物、试剂盒及方法 |
| CN107164474B (zh) * | 2017-05-22 | 2020-09-04 | 复旦大学附属华山医院 | 一种检测calr基因2型突变的引物组合物及试剂盒 |
| CN107164473B (zh) * | 2017-05-22 | 2020-08-25 | 复旦大学附属华山医院 | 一种检测calr基因1型突变的引物组合物及试剂盒 |
| CN108949971A (zh) * | 2017-05-23 | 2018-12-07 | 曹国君 | 钙网蛋白基因1型突变检测用封闭pna探针 |
| CN107462706A (zh) * | 2017-08-01 | 2017-12-12 | 广西中医药大学附属瑞康医院（广西中西医结合医院） | 一种肿瘤试剂盒 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| CN108434439B (zh) * | 2018-01-23 | 2020-02-07 | 中国人民解放军总医院 | 钙网蛋白的医药用途 |
| US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| RU2679653C1 (ru) * | 2018-08-01 | 2019-02-12 | Общество с ограниченной ответственностью "Формула гена" | Набор реактивов для выявления Ph-негативных миелопролиферативных новообразований и способ диагностики на его основе |
| EP3870572B1 (en) | 2018-10-23 | 2026-05-06 | Myelopro Diagnostics and Research GmbH | Compounds targeting mutant calreticulin |
| SG11202109056TA (en) * | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Multifunctional molecules that bind to calreticulin and uses thereof |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| EP3932952A4 (en) * | 2019-02-28 | 2022-11-30 | Juntendo Educational Foundation | ANTIBODIES BINDING TO TRUNKED MUTANT CALRETICULIN AND DIAGNOSTIC, PROPHYLACTIC OR THERAPEUTIC DRUG FOR MYELOPROLIFERATIVE NEOPLASMA |
| WO2021039958A1 (ja) * | 2019-08-30 | 2021-03-04 | 東洋鋼鈑株式会社 | 骨髄増殖性腫瘍に関連する遺伝子変異評価用キット |
| IL270306A (en) | 2019-10-30 | 2021-05-31 | Yeda Res & Dev | Prevention and treatment of pre-myeloid and myeloid malignancies |
| CN112795647B (zh) * | 2019-11-14 | 2022-08-16 | 北京肿瘤医院(北京大学肿瘤医院) | 一种肿瘤标志物及其应用 |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2021188619A1 (en) * | 2020-03-17 | 2021-09-23 | Memorial Sloan Kettering Cancer Center | Heteroclitic cancer vaccines |
| WO2022045247A1 (ja) | 2020-08-27 | 2022-03-03 | 学校法人順天堂 | 抗切断型変異ｃａｌｒ－ｃｄ３二重特異性抗体及び医薬組成物 |
| AU2023226293A1 (en) | 2022-02-25 | 2024-09-05 | Juntendo Educational Foundation | Medicine comprising combination of anti-mutant-calr antibody and another drug |
| WO2023245139A2 (en) * | 2022-06-17 | 2023-12-21 | Icahn School Of Medicine At Mount Sinai | Mutant calr-peptide based vaccine |
| CN117003866B (zh) * | 2023-08-23 | 2025-06-06 | 复旦大学附属华山医院 | 一种抗calr突变蛋白抗体、制备方法及检测试剂盒 |
| JP1773328S (ja) * | 2024-02-13 | 2024-06-18 | サセプタ | |
| WO2025207632A1 (en) * | 2024-03-26 | 2025-10-02 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for the treatment of myeloproliferative neoplasms |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20493A (en) * | 1858-06-08 | Bebtch-plaite | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3486459D1 (de) | 1983-09-26 | 1997-12-11 | Udo Dr Med Ehrenfeld | Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| US5846727A (en) * | 1996-06-06 | 1998-12-08 | Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College | Microsystem for rapid DNA sequencing |
| AU7022898A (en) | 1997-04-23 | 1998-11-13 | Ontario Cancer Treatment & Research Foundation | Calreticulin-deficient cells |
| JP2004515209A (ja) * | 2000-04-05 | 2004-05-27 | ゲノム セラピューティックス コーポレーション | １１ｑ１３．３の高骨量遺伝子 |
| US7205146B1 (en) | 2000-06-14 | 2007-04-17 | Oscient Pharmaceuticals Corporation | Nucleotide and amino acid sequences relating to respiratory diseases and obesity |
| US6426220B1 (en) * | 2000-10-30 | 2002-07-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of calreticulin expression |
| US20020147165A1 (en) * | 2001-02-22 | 2002-10-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of calreticulin expression |
| GB0113266D0 (en) * | 2001-05-31 | 2001-07-25 | Bayer Ag | Genes and proteins for prevention prediction diagnosis prognosis and treatment of chronic lung disease |
| WO2006081323A2 (en) | 2005-01-26 | 2006-08-03 | The Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin |
| JP4616237B2 (ja) | 2006-11-07 | 2011-01-19 | 日本電信電話株式会社 | シリコン化合物薄膜の形成方法 |
| CN101616029B (zh) † | 2009-07-28 | 2011-10-26 | 中兴通讯股份有限公司 | 一种实现网络拓扑发现的方法及系统 |
| WO2011069004A1 (en) * | 2009-12-04 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Mpl mutations in jak2 v617f negative patients with myeloproliferative disease |
| WO2012088309A1 (en) | 2010-12-21 | 2012-06-28 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor |
| CN103091499B (zh) * | 2013-01-23 | 2015-07-08 | 三峡大学 | 一种肿瘤标志物钙网蛋白检测试剂盒的制备及应用 |
| EP2808338B1 (en) | 2013-09-16 | 2016-03-30 | CeMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH | Mutant calreticulin for the diagnosis of myeloid malignancies |
-
2014
- 2014-09-15 EP EP14184835.8A patent/EP2808338B1/en active Active
- 2014-09-15 CA CA2924370A patent/CA2924370C/en active Active
- 2014-09-15 SG SG11201601193TA patent/SG11201601193TA/en unknown
- 2014-09-15 ES ES14184835.8T patent/ES2577289T3/es active Active
- 2014-09-15 DK DK18215718.0T patent/DK3494985T3/da active
- 2014-09-15 RU RU2016114509A patent/RU2668808C2/ru active
- 2014-09-15 ES ES17205289T patent/ES3068287T3/es active Active
- 2014-09-15 US US14/486,973 patent/US9371570B2/en active Active
- 2014-09-15 PL PL14184835.8T patent/PL2808338T3/pl unknown
- 2014-09-15 PT PT141848358T patent/PT2808338E/pt unknown
- 2014-09-15 WO PCT/EP2014/069638 patent/WO2015036599A1/en not_active Ceased
- 2014-09-15 KR KR1020167008252A patent/KR102433548B1/ko active Active
- 2014-09-15 DK DK15196254.5T patent/DK3020727T4/da active
- 2014-09-15 MX MX2016003245A patent/MX348980B/es active IP Right Grant
- 2014-09-15 JP JP2016542333A patent/JP6745220B2/ja active Active
- 2014-09-15 EP EP18215718.0A patent/EP3494985B1/en active Active
- 2014-09-15 US US15/021,906 patent/US10344335B2/en active Active
- 2014-09-15 EP EP17205289.6A patent/EP3339318B1/en active Active
- 2014-09-15 CN CN201480062698.8A patent/CN105916876A/zh active Pending
- 2014-09-15 CN CN202610089526.4A patent/CN121951043A/zh active Pending
- 2014-09-15 PL PL18215718T patent/PL3494985T3/pl unknown
- 2014-09-15 EP EP26162535.4A patent/EP4733417A3/en active Pending
- 2014-09-15 BR BR112016005611-6A patent/BR112016005611B1/pt active IP Right Grant
- 2014-09-15 AU AU2014320262A patent/AU2014320262B2/en active Active
- 2014-09-15 EP EP15196254.5A patent/EP3020727B2/en active Active
- 2014-09-15 DK DK14184835.8T patent/DK2808338T3/da active
- 2014-09-15 CN CN202110912310.0A patent/CN113564254A/zh active Pending
-
2018
- 2018-02-22 US US15/902,859 patent/US20180251852A1/en not_active Abandoned
-
2019
- 2019-06-12 US US16/438,575 patent/US11274350B2/en active Active
- 2019-09-11 AU AU2019229353A patent/AU2019229353B2/en not_active Ceased
-
2022
- 2022-02-16 US US17/673,686 patent/US20220251666A1/en active Pending
- 2022-11-04 JP JP2022177306A patent/JP7646221B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11939374B2 (en) | Treatment of fibrosis | |
| JP6196338B2 (ja) | 診断および治療のための腫瘍関連抗原の同定 | |
| RU2016114509A (ru) | Мутантный кальретикулин для диагностики миелоидных новообразований | |
| JP6285472B2 (ja) | 診断及び治療のための腫瘍関連マーカーの同定 | |
| JP2021534810A (ja) | Ｒｎａを編集する方法および組成物 | |
| JP6045563B2 (ja) | ドミナントネガティブｈｓｐ１１０突然変異体、並びにガンの予測及び処置におけるその使用 | |
| KR102138131B1 (ko) | 뇌 종양 동물 모델 및 이의 제조 방법 | |
| US20250277786A1 (en) | Gene activation targets for enhanced human t cell function | |
| CN109072312A (zh) | 癌症表观遗传谱分析 | |
| JPWO2019093502A1 (ja) | がん促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法 | |
| JP2024019511A (ja) | がんにおける融合遺伝子 | |
| JP7177439B2 (ja) | 炎症促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法 | |
| JPWO2018030459A1 (ja) | 膵がんでのｃｌｄｎ１８−ａｒｈｇａｐ６融合遺伝子又はｃｌｄｎ１８−ａｒｈｇａｐ２６融合遺伝子の検出 | |
| JPWO2015033565A1 (ja) | 癌の診断、阻害剤のスクリーニングにおけるｒｈｏａの使用 | |
| AU2017285726A1 (en) | Methods for diagnosing and treating metastatic cancer | |
| JP2007534772A (ja) | ヒト肝細胞癌細胞を特異的に標的化するための方法および組成物 | |
| WO2015129655A1 (ja) | Ｄｎａｊｂ１－ｐｒｋａｃａ遺伝子の検出方法 | |
| US8309687B2 (en) | Biomarker specific for cancer | |
| EP3347455A1 (en) | Methods and compositions for modulating monocyte populations and related uses thereof | |
| JP2014054185A (ja) | 新規ｂｒａｆ融合体の検出法 | |
| WO2015023110A1 (ko) | 종양 질환 진단용 바이오마커 및 이의 용도 | |
| KR101748774B1 (ko) | 돼지 백혈구 항원(sla)-mic2 유전자의 다형성 분석방법 | |
| HK40102969A (en) | Gene activation targets for enhanced human t cell function | |
| JP2024500804A (ja) | Ｃｈｄ２ハプロ不全の処置における使用のための組成物及びその同定方法 | |
| RU2019144018A (ru) | Варианты b4galt1 и их применение |